AGA Family of Websites: Gastro.org

Functional heartburn or refractory reflux disease?

AGA has released a new Clinical Practice Update providing best practice advice to diagnosis and treat functional heartburn.
WomanHeartburnDoctor_960x640
WomanHeartburnDoctor_960x640

Functional heartburn is important to recognize because without investigation, this condition might be considered equivalent with gastroesophageal reflux disease (GERD), and treating physicians could continue acid suppressive therapy unnecessarily or escalate antireflux treatments, which might even lead to harm.

In the AGA Clinical Practice Update on Functional Heartburn: Expert Review, published in Gastroenterology’s June issue, the authors provide the following best practice advice statements to address key issues in the clinical management of these patients:

CLINICAL PRACTICE ADVICE

  1. A diagnosis of functional heartburn should be considered when retrosternal burning pain or discomfort persists despite maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately before meals during a three-month period.
  2. A diagnosis of functional heartburn requires upper endoscopy with esophageal biopsies to rule out anatomic and mucosal abnormalities, esophageal high-resolution manometry to rule out major motor disorders, and pH monitoring off PPI therapy (or pH-impedance monitoring on therapy in patients with proven GERD), to document physiologic levels of esophageal acid exposure in the distal esophagus with absence of reflux–symptom association (ie, negative symptom index and symptom association probability).
  3. Overlap of functional heartburn with proven GERD is diagnosed according to Rome IV criteria when heartburn persists despite maximal PPI therapy in patients with a history of proven GERD (ie, positive pH study, erosive esophagitis, Barrett’s esophagus or esophageal ulcer), and pH impedance testing on PPI therapy demonstrates physiologic acid exposure without reflux–symptom association (ie, negative symptom index and symptom association probability).
  4. PPIs have no therapeutic value in functional heartburn, the exception being proven GERD that overlaps with functional heartburn.
  5. Neuromodulators, including tricyclic antidepressants, selective serotonin reuptake inhibitors, tegaserod and histamine-2 receptor antagonists have benefit as either primary therapy in functional heartburn or as add-on therapy in functional heartburn that overlaps with proven GERD.
  6. Based on available evidence, acupuncture and hypnotherapy may have benefit as monotherapy in functional heartburn, or as adjunctive therapy combined with other therapeutic modalities.
  7. Based on available evidence, anti-reflux surgery and endoscopic GERD treatment modalities have no therapeutic benefit in functional heartburn and should not be recommended.

For more information, view the full AGA Clinical Practice Update on Functional Heartburn: Expert Review.

Stay in the know with AGA

Members receive our weekly newsletter, AGA eDigest, which is packed with clinical education updates, career development opportunities, member news and more.

Stay connected. Stay informed. Stay ahead.

AGA clinical guidance

Find the latest evidence-based recommendations for treating your patients.

X
American Gastroenterological Association
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.